COMPEL study shows continuing osimertinib treatment through progression with the addition of chemotherapy improves progression-free survival in EGFR-mutated NSCLC
Reports and Proceedings
Updates every hour. Last Updated: 2-Nov-2025 03:11 ET (2-Nov-2025 08:11 GMT/UTC)